A G Gutsalyuk

City Clinical Hospital named after A.K. Eramishantsev, Moscow, Russia.

2 publications 2023 – 2025 ORCID
RussiaIschemic StrokeFibrinolytic AgentsTissue Plasminogen ActivatorThrombolytic Therapy

What does A G Gutsalyuk research?

A G Gutsalyuk studies ischemic stroke (IS), which occurs when blood flow to the brain is blocked. They specifically investigate how well the medication Revelise (alteplase) works for patients experiencing this condition, particularly in practical, everyday medical settings. Their research looks into various factors like patient age and existing health conditions to see how these aspects influence recovery and treatment outcomes. Their findings help doctors and patients understand the potential benefits of this treatment over time.

Key findings

  • In a study of 2,202 patients, nearly half (49.9%) experienced good outcomes upon discharge after receiving Revelise for ischemic stroke.
  • After 90 days, the rate of patients reporting good outcomes increased to 66.4%, showing significant improvement over time.
  • The research indicates that Revelise effectively reduces disabilities related to strokes, even among older patients and those with other health issues.

Frequently asked questions

Does Dr. Gutsalyuk study ischemic stroke?
Yes, Dr. Gutsalyuk focuses on ischemic stroke and the effectiveness of treatments like Revelise.
What treatments has Dr. Gutsalyuk researched?
Dr. Gutsalyuk has researched thrombolytic therapy, particularly the medication Revelise, for treating ischemic stroke.
Is Dr. Gutsalyuk's work relevant to older patients?
Yes, their research includes a significant number of older patients, demonstrating the effectiveness of treatment even for this age group.
What outcomes can patients expect from treatments studied by Dr. Gutsalyuk?
Patients can expect that nearly 50% will have good outcomes after treatment, which improves to 66.4% after 90 days.

Publications in plain English

[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].

2025

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more

Plain English
This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues. Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.

PubMed

[Craniocerebral hypothermia in the acute period of ischemic stroke].

2023

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Gutsalyuk AG, Petrova MV, Borozenets KF, Shevelev OA, Grechko AV +5 more

Plain English
This study looked at the effects of cooling the brain (craniocerebral hypothermia) on patients with moderate ischemic stroke. Researchers found that patients who received this cooling treatment saw their neurological problems improve dramatically—they had a 75% reduction in symptoms after just one day, and a 93.75% improvement by discharge, compared to only 35% and 55% improvement in the control group. This is important because it shows that cooling the brain can lead to better recovery after a stroke without any serious side effects. Who this helps: This helps stroke patients by providing a more effective treatment option for recovery.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.